Treatment with the PPARδ agonist GW0742, through the targeting of the METRNL-E2F-PPARδ pathway, reduces the maximal respiratory capacity of METRNL, thereby inhibiting the growth of orthotopic gliomas in mice, as well as flank prostate and colorectal cancer [130]. This evidence concerns the gene PPARD and central nervous system cancer.